1 The phytoestrogenic compound trans-resveratrol (trans-3,5,4'-trihydroxystilbene) is found in appreciable quantities in grape skins and wine. It has been shown that both products rich in transresveratrol and pure trans-resveratrol inhibit platelet aggregation both in vivo and in vitro. However the mechanism of this action still remains unknown. 2 An essential component of the aggregation process in platelets is an increase in intracellular free Ca 2+ ([Ca 2+ ] i ). Ca 2+ must enter the cell from the external media through speci®c and tightly regulated Ca 2+ channels in the plasma membrane. The objective of this study was to characterize what eect trans-resveratrol had on the Ca 2+ channels in thrombin stimulated platelets. 3 In this study we showed that trans-resveratrol immediately inhibited Ca 2+ in¯ux in thrombinstimulated platelets with an IC 50 of 0.5 mM. trans-Resveratrol at 0.1, 1.0 and 10.0 mM produced 20+6, 37+6 and 57+4% inhibition respectively of the eect of thrombin (0.01 u ml 71 ) to increase [Ca 2+ ] i . 4 trans-Resveratrol also inhibited spontaneous Ba 2+ entry into Fura-2 loaded platelets, with 0.1, 1.0 and 10.0 mM trans-resveratrol producing 10+5, 30+5 and 50+7% inhibition respectively. This indicated that trans-resveratrol directly inhibited Ca 2+ channel activity in the platelets in the absence of agonist stimulation. 5 trans-Resveratrol also inhibited thapsigargin-mediated Ca 2+ in¯ux into platelets. This suggests that the store-operated Ca 2+ channels are one of the possible targets of trans-resveratrol. These channels rely on the emptying of the internal Ca 2+ stores to initiate in¯ux of Ca 2+ into the cell. 6 The phytoestrogens genistein, daidzein, apigenin and genistein-glucoside (genistin) produced inhibitory eects against thrombin similar to those seen with trans-resveratrol. 7 We conclude that trans-resveratrol is an inhibitor of store-operated Ca 2+ channels in human platelets. This accounts for the ability of trans-resveratrol to inhibit platelet aggregation induced by thrombin.
Introduction
Platelets, the major hemostatic cell in blood, are formed in the bone marrow from the precursor cell megacaryocytes (Heyns, 1994) . Structurally, platelets contain no nucleus and have a large number of granules (dense granules and a-granules) for the storage of biologically active compounds such as serotonin, ADP and platelet derived growth factor (White, 1994) . The contents of the granules are released upon platelet activation. The intracellular dense tubular system (analogous to the endoplasmic reticulum) serves as a calcium storage site (Crawford & Scrutton, 1994) .
Platelets are activated by multiple factors (agonists) produced at the site of vascular injury (Brass et al., 1993; Hourani & Cusack, 1991) . These factors include ADP, collagen, thromboxane A 2 and thrombin, the most potent platelet activator. Upon activation, platelets undergo shape change, express ®brinogen receptors, aggregate and release their granule contents. As a result a hemostatic plug is formed on a ®brin meshwork thus sealing the damaged blood vessel.
Excessive platelet aggregation however plays a role in the development of thrombosis and therefore it is important that this process is properly regulated for the ecient functioning of the cardiovascular system.
The major intracellular stimulus involved in platelet aggregation is an increase in free cytosolic calcium concentration ([Ca 2+ ] i ) (Sage & Rink, 1990) . As in most non-excitable cells the increase in platelet [Ca 2+ ] i induced by various agonists involves both in¯ux of extracellular calcium through plasma membrane calcium channels and mobilization of intracellular calcium from the dense tubular system (Berridge, 1997; Heemskerk & Sage, 1994; Sage, 1997) .
The pathway(s) of the calcium entry in platelets share common properties with the calcium entry pathways found in other non-excitable cells. The mechanism of calcium release from the myo-inositol 1,4,5-P 3 (IP 3 )-sensitive internal stores is well characterized. On the other hand, the mechanism of the calcium in¯ux pathway in platelets is still not completely resolved (Sage, 1997) . Calcium from the external medium enters the cell through speci®c ion channels of several dierent types. Platelets, according to Sage (1997) , lack voltage-gated calcium channels, so the change in the membrane potential does not generate calcium in¯ux, and platelets are reported not to bind verapamil and nifedipine. Instead, receptor-mediated calcium entry (RMCE) through the plasma membrane channel following binding of a ligand to its membrane receptor seems to be responsible for calcium in¯ux into platelets. RMCE channels may be one of the following types: ROC (receptoroperated channel), SMOC (second messenger operated channel) and SOCC (store-operating calcium channel) (Sage, 1997) . SOCC channels are activated to promote calcium in¯ux upon the emptying of the internal calcium stores (dense tubular system). The mechanism which links the depletion of the IP 3 -sensitive internal calcium stores to the SOCC have not yet been elucidated (Parekh & Penner, 1997; Clementi & Meldolesi, 1996) . There are currently two models proposed for activating SOCC: (1) the two kinds of channels (plasma membrane calcium channel and the intracellular endoplasmic reticulum IP 3 sensitive calcium channel) are coupled to each other by physical proximity or (2) the emptying of the internal stores generates a calcium in¯ux factor (CIF), which then acts on the plasma membrane calcium channels. The speci®c nature of CIF is poorly de®ned, however it may involve arachidonate metabolites and S-nitrosylation (e.g. Rzigalinski et al., 1996; Favre et al., 1998) .
A very important tool used to study SOCC is a plant derived tumor promoter known as thapsigargin (Thastrup et al., 1990) . Thapsigargin eectively inhibits the calcium ATPase pump of the endoplasmic reticulum without increasing the level of IP 3 . When the pump is inhibited, calcium is prevented from entering the intracellular stores. Stored calcium leaks into the cytoplasm, some of which is extruded from the cell by the plasma membrane Ca 2+ -ATPase pump. Consequently, store emptying evokes calcium in¯ux through SOCC in the plasma membrane (Parekh & Penner, 1997) .
It has been reported numerous times that consumption of certain foods, grapes and red wine, serve as a protective factor against coronary heart disease (CHD). The`French paradox' correlates the lower prevalence of CHD with the regular moderate consumption of red wine (Soleas et al., 1997) . The bene®cial eects of this product have been attributed to their high antioxidant/phytoestrogenic content (e.g. Miksicek, 1995; Williams & Rutledge, 1998) .
Phytoestrogens are naturally occurring antioxidant compounds, usually polyphenols, which are present in the variety of foods and beverages. Phytoestrogens derived their name for their ability to mimic the actions of oestrogens (female sex hormones). They can bind to the human oestrogen receptor and activate genomic oestrogen-response elements, although at a much higher concentration than the natural oestrogens (Miksicek, 1995; Gehm et al., 1997) . trans-Resveratrol (trans-3,5,4'-trihydroxystilbene) (Figure 1 ) is a phytoestrogenic compound found in grapes (Miksicek, 1995) , it possesses antitumor, antioxidative and antifungal activities (Jang et al., 1997; Tham et al 1998) .
trans-Resveratrol inhibits human platelet aggregation both in vitro and in vivo (Pace-Asciak et al., 1995; 1996; Bertelli et al., 1995) . This has important implications in ascribing how the intake of phytoestrogens in food can help prevent thrombosis, essentially serving as a blood thinner, having potentially bene®cial eects on the cardiovascular system. However, the mechanism by which trans-resveratrol inhibits platelet aggregation has not been elucidated. Since aggregation can not occur without a sucient increase in the [Ca 2+ ] i , the goal of the present study was to establish if dietary phytoestrogens, such as trans-resveratrol, could have an eect on the calcium channels in stimulated human platelets.
Phytoestrogenic iso¯avonoids genistein and daidzein and the¯avonoid apigenin (Figure 1 ) are also encountered in foods such as soy beans and were also examined brie¯y in this study. Genistein is also known as a potent tyrosine kinase inhibitor (Jayatilake et al., 1993) , and is also known to inhibit certain tumor cell growth (e.g. Fioravanti et al., 1998) . Previous studies have shown that 100 mM genistein but not daidzein was able to inhibit ADP and thrombin induced calcium in¯ux in human platelets (Sargeant et al., 1993a,b) , it was concluded that tyrosine phosphorylation controlled calcium entry. Our ®ndings are more consistent with genistein and daidzein having a more direct eect on calcium channels.
Methods

Reagents and material sources
The following were from Sigma Chemical Co: trans-resveratrol, apigenin (4',5,7-trihydroxy¯avone), genistein (4',5,7-trihydroxyiso¯avone), genistein-7-O-D-glucoside (genistin), daidzein (4',7-dihydroxyiso¯avone), thrombin, Me 2 SO (dimethylsulphoxide) and EGTA [ethylene glycol-bis(b-aminoethyl ether) 
Blood donors and platelet preparation
All donors were healthy volunteers (aged 20 ± 40 years) who had not consumed any medication known to aect platelet function (e.g. calcium channel blockers and aspirin) for at least 10 days prior to the study. Venous blood was collected into 1/10 volume of ACD (74.8 mM sodium citrate, 38.1 mM citric acid and 123 mM dextrose pH 6.4) (Baxter Healthcare Corp.). The blood was centrifuged at 2506g for 10 min at room temperature to obtain platelet rich plasma (PRP). The PRP was centrifuged at 5506g for 12 min to sediment the platelets. The platelets were then re-suspended in a modi®ed Tyrodes physiological salt solution (in mM): NaCl 145, KCl 4, MgSO 4 1, Na 2 HPO 4 0.5, Na/HEPES 10, glucose 6, pH 7.4, containing 1.0 mM EGTA which acted to prevent spontaneous aggregation during the various experimental manipulations by binding extracellular Ca 2+ (Nolan & Lapetina, 1990) . The platelets were washed once (5006g for 15 min) and ®nally re-suspended at a count of approximately 3610 8 platelets ml 71 .
Phytoestrogen solution preparations
Stock solutions of the phytoestrogens (trans-resveratrol, genistein, daidzein, apigenin) in Me 2 SO (3 mg ml 71 ) were prepared and stored at 7208C. Just before each experiment aliquots were thawed and diluted with Me 2 SO up to a desirable concentration (see speci®c ®gure legends). Stock solutions of phytoestrogens were diluted 200 fold into the spectro¯uorometric cuvette to give the desired ®nal concentration.
Platelet loading with fura-2 and measurement of [Ca 2+ ] i Intracellular calcium measurements [Ca 2+ ] i employed thē uorescent dye fura-2, which involved incubating the platelets with the cell permeant acetoxymethyl ester (fura-2/AM) (e.g. Sargeant et al., 1992) . A suspension of human platelets (isolated as described above) was incubated with 2 mM fura-2/AM for 1 h at room temperature (on a rocking platform). Excess fura-2/AM was removed by centrifugation (5006g for 10 min) and the platelets suspended in fresh buer, without added EGTA. Aliquots of platelet suspension (0.5 ml) were added to 1.0 ml cuvettes containing a Te¯on coated stirrer bar (Chrono-log, Havertown, PA, U.S.A.). Just before [Ca 2+ ] i measurements were performed, Ca 2+ was added back to the buer to a ®nal concentration of 2 mM, then phytoestrogens (various concentrations in 2.5 ml) and thrombin 0.01 u ml 71 were added (see individual Figure legends for speci®c details). The eects of trans-resveratrol and other phytoestrogens to inhibit the actions of thrombin (see Results) were immediate. In preliminary experiments we added trans-resveratrol together with thrombin and the inhibitory eect was the same as if we preincubated the trans-resveratrol for 5 ± 10 s or 120 min before thrombin. trans-Resveratrol therefore produced an immediate blockade of calcium in¯ux channel. Also when trans-resveratrol was added 60 s after thrombin, the [Ca 2+ ] i declined immediately to a value approaching the inhibitory eect observed when trans-resveratrol was added just prior to the addition of thrombin. The measurements of [Ca 2+ ] i were performed at room temperature in a SPEX ] i in thrombinstimulated platelets. Calcium 2 mM was added to the platelet suspension 20 s before data collection started (zero time). Ten seconds later, trans-resveratrol solution was added to yield a ®nal concentration in the platelet suspension of either 0.1, 1.0 or 10 mM. Thrombin (0.01 u ml 71 ) was added 10 s later. Thrombin caused a large increase in [Ca 2+ ] i in the control condition, platelets started to aggregate at 60 ± 80 s. All three concentrations of trans-resveratrol inhibited the thrombin-induced rise in [Ca 2+ ] i in a dose-dependent manner. The trace shown is from a representative experiment; similar results were obtained from six other platelet preparations and are presented in Figure 3 . ] i and Ba 2+ ion in¯ux. The % inhibitory eect of trans-resveratrol was calculated by subtracting the basal or pre-stimulated value from the peak eect with trans-resveratrol present and comparing it to the eect observed in the control with thrombin and without trans-resveratrol. The IC 50 was 0.5 mM for both parameters, and was calculated by estimating the concentration of trans-resveratrol that produced 50% inhibition of the maximum inhibitory eect which was 57% inhibition of the [Ca 2+ ] i response, and 50% inhibition of the barium ion in¯ux response. These values were 28.5% for [Ca 2+ ] i (i.e. 1/2 of 57%) and 25% for barium ion in¯ux (i.e. 1/2 of 50%). The data represent mean+s.e.mean from six separate experiments with dierent platelet donors, typical experiments are shown in Figures 2 and 7. Statistical signi®cance of transresveratrol eect when compared to thrombin control: *P50.05, **P50.01.
trans-Resveratrol inhibits platelet Ca
2+ influx 151 Y. Dobrydneva et al ARCM spectro¯uorometer using excitation wavelengths of 340 and 380 nm and an emission wavelength of 505 nm. Calibration was performed as previously described for human sperm (Blackmore et al., 1990 , it cannot be extruded from the cell by plasma membrane Ca 2+ -ATPase pump therefore it accumulates in the cell (Ozaki et al., 1992; Zschauer et al., 1988; Blache & Clavatti, 1987; Blache et al., 1887) After Ca 2+ was added back to the platelet suspensions, thapsigargin (dissolved in Me 2 SO) was added to the platelet suspension to a ®nal concentration of 10 77 M and thē uorescence was monitored as described previously.
Statistical analysis
Data are reported as mean+s.e.mean for the number of individual experiments speci®ed in the Figure legends. Comparisons were made using Student's t-test, with a P value 50.05 considered signi®cant. Dierent platelet donors were used for each experiment.
Results
Eects of trans-resveratrol on thrombin-induced [Ca 2+ ] i increase in human platelets
Treatment of the platelet suspension with trans-resveratrol markedly reduced the elevation of the [Ca 2+ ] i in response to the thrombin. The data in Figure 2 shows a representative experiment in which three dierent concentrations of trans- ] i when calcium was removed from the external medium, compare to data in Figure 4 . transResveratrol 10 mM produced a small inhibition of thrombin to mobilize internal calcium, although the inhibitory eect was not statistically signi®cant (see text for actual values). The data in Figure  5 (no calcium plus EGTA) is directly comparable to the data shown in Figure 4 (with 2.0 mM calcium) since the same platelet preparation was used in both experiments. The trace shown is from a representative experiment; similar results were obtained from three other platelet preparations.
trans-Resveratrol inhibits platelet Ca
2+ influx 152 Y. Dobrydneva et al resveratrol were added to platelets. The eect of transresveratrol was observed after a short 5 ± 10 s incubation with trans-resveratrol before adding thrombin. It takes 5 ± 10 s for complete mixing of the 2.5 ml aliquot of the trans-resveratrol solution in the 500 ml aliquot of platelet suspension in the spectro¯uorometric cuvette using a magnetic stirrer bar. transResveratrol reduced both the rate of [Ca 2+ ] i rise together with the peak level of [Ca 2+ ] i induced by thrombin. The data in Figure 3 is an average of six experiments, similar to that shown in Figure 1 , and shows that trans-resveratrol produced a dosedependent inhibition of the [Ca 2+ ] i increase with an IC 50 of 0.5 mM, see Figure 3 legend for details. The data shows that 0.1, 1.0 and 10.0 mM trans-resveratrol produced statistically signi®cant inhibitory eects of 20+6% (P50.01), 37+6% (P50.001) and 57+4% (P50.001). The maximum degree of inhibition (57+4%) was observed with 10 mM trans-resveratrol, higher concentrations of trans-resveratrol were not used because they caused large changes in¯uorescence that interfered with the fura-2¯uorescence measurements (data not shown). Cholesterol (negative control steroid) at a concentration of 10 mM, and the Me 2 SO solvent (0.5% v v 71 ) used to dissolve trans-resveratrol did not in¯uence [Ca 2+ ] i levels (data are not shown). trans-Resveratrol did not interfere with the calcium ionophore ionomycin (10.0 mM) or digitonin (0.01%) induced [Ca 2+ ] i elevations in human platelets, thereby demonstrating that trans-resveratrol does not in¯uence fura-2¯uorescence and therefore rules out any non-speci®c eects of the phytoestrogen on the [Ca 2+ ] i measurements. Both these agents increase [Ca 2+ ] i by mechanisms independent of plasma membrane calcium channels.
The data in Figure 4 depicts a representative experiment that indicates trans-resveratrol alone did not have an eect on [Ca 2+ ] i level in the absence of thrombin stimulation. In the same experiment trans-resveratrol blocked the thrombin eect similar to that shown in Figure 2 , although in this particular experiment the inhibitory eect was larger. The elevation of [Ca 2+ ] i in thrombin stimulated platelets, without the addition of Ca 2+ to the medium together with 5.0 mM EGTA added to the buer, was substantially smaller (25 nM increase, Figure 5 ), compared with [Ca 2+ ] i elevation in the presence of the external Ca 2+ (500 nM increase, Figure 4 ). The elevation of [Ca 2+ ] i induced by thrombin in EGTA containing media was 7+2% of that seen in the presence of 2.0 mM calcium (average from three separate experiments). This suggested that the majority of the [Ca 2+ ] i increase, due to thrombin (0.01 u ml 71 ) stimulation, was primarily due to Ca 2+ in¯ux, and not the result of the emptying of the internal Ca 2+ stores. The data in Figure 5 showed that 10 mM trans-resveratrol produced a very small inhibition of the thrombin-induced internal mobilization of calcium. The average of four separate experiments showed that 10.0, 1.0 and 0.1 mM trans-resveratrol produced an 8+10, 2+11 and 12+11% inhibition respectively of thrombin, these small inhibitory eects were not statistically signi®cant (P40.05).
Extracellular calcium in the concentration range of 50 ± 4000 mM did not overcome the trans-resveratrol inhibition of Ca 2+ in¯ux into the thrombin-stimulated platelets ( Figure 6 ). The eect of trans-resveratrol to inhibit thrombin-induced increases in [Ca 2+ ] i was very small (not statistically signi®cant, P40.05) when the extracellular calcium was in the 50 ± 250 mM range. This is consistent with the data shown in Figure 5 in which trans-resveratrol produced a small but not statistically signi®cant inhibition (see above) of thrombin in the presence of extracellular EGTA and no added calcium. When the extracellular calcium was increased to 500 ± 4000 mM, thrombin was then able to promote a much larger increase in [Ca 2+ ] i due to a greater calcium in¯ux and the eect of trans- Figure 6 Dose response of extracellular calcium on the ability of thrombin to increase [Ca 2+ ] i in the presence and absence of transresveratrol. Various concentrations of calcium were added to the medium 20 s before data collection was started (zero time). Thrombin 0.01 u ml 71 was then added to the platelets in the presence and absence of 10 mM trans-resveratrol as described in the legend to Figure 2 . The data shown is the mean+s.e.mean from three separate experiments.*P40.05, **P50.05. ] i as indicated by a small increase in the 340/380 nm ratio. The trace shown is from a representative experiment, similar results were obtained from six other platelet preparations. The dose response of trans-resveratrol to inhibit Ba 2+ in¯ux into platelets is shown in Figure 3 .
2+ influx 153 Y. Dobrydneva et al resveratrol was much more pronounced (Figures 4 and 6) . The degree of inhibition induced by trans-resveratrol remained constant as the Ca 2+ concentration increased in the 1000 ± 4000 mM range (Figure 6 ).
Eect of trans-resveratrol on the basal Ca 2+ channel activity measured by monitoring Ba 2+ uptake
Non-stimulated (control) platelets exhibit a biphasic (an early and a late component) rise in Ba 2+ possibly due to at least two dierent populations of Ca 2+ channels, which are accessible for Ba 2+ entry (Figure 7) . In most of the experiments the in¯ux of Ba 2+ began to induce platelet aggregation after 2 min. The rational for examining basal Ba 2+ in¯ux in the absence of thrombin was that the in¯uence of various second messenger pathways (e.g. tyrosine phosphorylation, Ca 2+ store depletion, cyclic nucleotides) would not be involved and hence the eect of the various phytoestrogens would only be on the Ca 2+ in¯ux channels and not on any agonist stimulated signal transduction pathway(s). trans-Resveratrol produced a large inhibition of Ba 2+ in¯ux into the platelets, aecting mostly the later component of entry. Three dierent concentrations (0.1, 1.0 and 1.0 mM) of trans-resveratrol are shown in this representative experiment (Figure 7) . The dose-response of trans-resveratrol to inhibit Ba 2+ in¯ux from six dierent experiments is shown in Figure 3 , with 0.1, 1.0 and 10.0 mM trans-resveratrol producing 10+5 (P50.05), 30+5 (P50.01) and 50+7% (P50.01) inhibition respectively. Thapsigargin stimulated Ba 2+ in¯ux, both the rate of in¯ux and the magnitude of the in¯ux (Figure 7 ). This result shows that at least some of the Ba 2+ that enters the platelet is through SOCC (see also Figure 8 ). When thapsigargin was added to platelets in the absence of both calcium and Ba 2+ there was a small increase in the 340/380 nm ratio (Figure 7 ). This result demonstrates that thapsigargin was able to mobilize intracellular calcium stores and that these stores were relatively small in platelets. This result is consistent with the data in Figures 4 and 5 in which chelation of extracellular calcium with EGTA reduced the ability of thrombin to increase [Ca 2+ ] i by 93%. Even though thapsigargin only produced a small mobilization of intracellular calcium, it was sucient to promote a large Ba 2+ ion in¯ux through SOCC (Figure 7) .
Eect of trans-resveratrol on thapsigargin-induced Ca 2+ entry trans-Resveratrol markedly decreased, in a dose-dependent manner, thapsigargin-induced Ca 2+ in¯ux, which suggested that SOCC are one of the possible targets for trans-resveratrol in the platelets (Figure 8 ). This result is consistent with the data on Ba 2+ in¯ux shown in Figure 7 . Thapsigargin produced a delayed response to increase [Ca 2+ ] i , compared to that seen with thrombin (also see Figure 2) ] i value obtained in each run, this number was divided by 2, then this number was added to the basal value. The time it takes to reach this 50% ] i level in thrombin-stimulated platelets. Calcium was added to the platelet suspension to a concentration of 2.0 mM 20 s before data collection was started (zero time). Approximately 10 s later, either genistein, daidzein or apigenin was added to yield ®nal concentrations in the platelet suspension of 10 mM. Thrombin (0.01 u ml 71 ) was added approximately 10 s later. All three phytoestrogenic compounds inhibited the thrombin-induced rise in [Ca 2+ ] i in a similar manner to that seen with trans-resveratrol (Figures 2, 3 and 4) . The trace shown is from a representative experiment; similar results were obtained from four other platelet preparations.
trans-Resveratrol inhibits platelet Ca 2+ influxvalue, after thapsigargin addition with various concentrations of trans-resveratrol, was the time to reach the EC 50 . To normalize each experiment we expressed the data as % increase in time over the control. Therefore when 0.1, 1.0 and 10.0 mM trans-resveratrol was added the time for thapsigargin to reach the EC 50 was 20+6 (P50.01), 30+7 (P50.01) and 94+10% (P50.001), data from seven separate experiments. This data shows that the greater the inhibition by transresveratrol the greater the % increase in time to reach the EC 50 .
Eect of other phytoestrogens on the thrombin-induced [Ca 2+ ] i increase in human platelets
The phytoestrogens apigenin, daidzein, genistein, (Figure 1 ) as well as genistein-glycoside did not cause a change in the [Ca 2+ ] i when added to non-stimulated platelet suspension, similar to that observed with trans-resveratrol (Figure 4 ). All the above compounds caused a marked decrease in [Ca 2+ ] i , in thrombinstimulated platelets (Figure 9 ). Daidzein (10 mM) produced a 42+4% inhibition of thrombin, average from four experiments, genistein (10 mM) produced a 50+5% inhibition of thrombin, average from seven experiments and in three separate experiments 10 mM apigenin produced a 50+8% inhibition of thrombin. The degree of the inhibition produced by each phytoestrogen was similar to the inhibition caused by 10 mM trans-resveratrol, which was 57+4% (see Figures 2 and  3) . The IC 50 was 1 mM for each phytoestrogen tested.
The very rapid inhibitory action of apigenin, daidzein, and genistein (immediately upon contact with platelets) suggested that these compounds produced their eects on the platelet surface. To con®rm this suggestion, the addition of hydrophilic conjugates of these compounds should produce a similar inhibitory eect, since they are unlikely to be able to traverse the hydrophobic plasma membrane and hence will be con®ned to the extracellular space. One such analogue was commercially available, namely genistein-7-O-D-glucoside (4',5,7-trihydroxyiso¯avone-7-glucoside). The data in Figure 10 shows that genistein-7-O-D-glucoside produced an inhibitory eect similar to that of genistein, which implied that the eect was mediated by genistein-7-O-D-glucoside acting on the platelet surface and not on some intracellular target. Genistein-glucoside (10 mM) produced a 37+6% inhibition of thrombin in three separate experiments, while genistein (10 mM) produced a 50+5% inhibition of thrombin in seven separate experiments. The inhibitory eects of both agents were not signi®cantly dierent from each other.
Discussion
The inhibitory eect of trans-resveratrol on platelet aggregation has been described (Pace-Asciak et al., 1995; 1996; Bertelli et al., 1995) . However, little is known about the actual mechanism of this phenomena. The present study demonstrates for the ®rst time that trans-resveratrol signi®cantly inhibited Ca 2+ in¯ux into thrombin-stimulated platelets. Since a rise in the [Ca 2+ ] i is a necessary step for aggregation, we suggest that the Ca 2+ blocking action of trans-resveratrol was responsible for the observed inhibition of thrombin induced platelet aggregation in platelet rich plasma (Pace-Asciak et al., 1995; 1996; Bertelli et al., 1995) , which we have also con®rmed using washed human platelets. The mode of inhibition was very rapid (several seconds preincubation), essentially at the moment of contact with the platelets. Incubating the platelets for longer periods (up to 120 min) with trans-resveratrol did not produce any further inhibitory eect (data not shown). Studies performed in polymorphonuclear leukocytes (PMN) demonstrated that trans-resveratrol was able to inhibit formyl methionyl leucyl phenylalanine (fMLP) induced elevations of [Ca 2+ ] i (Rotondo et al., 1998) . The PMN's do not appear to be as responsive to trans-resveratrol as the platelets are in our present study. The rise in [Ca 2+ ] i in the PMN's was inhibited slightly by 22 mM trans-resveratrol, with near maximum inhibition seen with 110 mM trans-resveratrol (Rotondo et al., 1998) . The elevation of [Ca 2+ ] i in platelets induced by thrombin was seen with as little as 0.1 mM trans-resveratrol, with a maximum 57+4% inhibition seen with 10 mM transresveratrol (Figure 3) . We did not use amounts of transresveratrol higher than 10 mM due to its insolubility at higher concentrations, and the quenching of the fura-2¯uorescence.
The question remains whether trans-resveratrol acts immediately on the platelet Ca 2+ channels or whether inhibition of Ca 2+ in¯ux is a secondary phenomenon to some other unknown primary eect of trans-resveratrol. It is possible that trans-resveratrol and other phytoestrogens generate an inhibitory second messenger to block calcium in¯ux, such as cyclic AMP or cyclic GMP (Sage, 1997) . However, the ®nding that trans-resveratrol inhibited the basal activity of Ca 2+ channels, measured by measuring Ba 2+ ion in¯ux in non-stimulated platelets, suggested that transresveratrol may have a binding site on the cell surface, thus directly aecting the channel itself. The ®rst component of Ba 2+ entry seems to remain unaected by trans-resveratrol, however the second component was inhibited dramatically. An IC 50 of 0.5 mM was estimated for trans-resveratrol to block Ba 2+ in¯ux (Figure 3 ). The phenomena, where transresveratrol immediately inhibited Ba 2+ in¯ux into platelets, Figure 10 Genistein-7-D-glucoside inhibited calcium in¯ux into thrombin-stimulated platelets in a manner similar to that of genistein. Calcium was added to the platelet suspension to a concentration of 2.0 mM 20 s before data collection starts (zero time). Approximately 5 s later, either genistein or genistein-7-D-glucoside was added to yield ®nal concentration in the platelet suspension of 10 mM. Thrombin (0.01 u ml 71 ) was added at approximately 10 s after data collection started. No phytoestrogens were added to the platelets in the thrombin control experiment. Both compounds inhibited the thrombin-induced rise in [Ca 2+ ] i in a similar manner. The trace shown is from a representative experiment; similar results were obtained from three other platelet preparations.
trans-Resveratrol inhibits platelet Ca 2+ influxsupports the hypothesis that ionic channels are involved. Since basal Ba 2+ in¯ux is independent from the generation of second messengers (no agonist used), trans-resveratrol probably acts on the channel directly.
The apparent target for trans-resveratrol action seems to be the SOCC, since thapsigargin mediated increases in [Ca 2+ ] i are also inhibited by trans-resveratrol (Figure 8 ). This is consistent with the fact that thrombin stimulated Ca 2+ in¯ux is primarily through the SOCC. Experiments also suggested that transresveratrol was unable to inhibit thrombin induced release of intracellular stored Ca 2+ (Figure 5 ), although a very small, not statistically signi®cant, inhibition was observed. Though it appears that trans-resveratrol acts on the platelet surface, there is still a possibility that a very small inhibition of internal Ca 2+ release may translate into an inhibition of the plasma membrane Ca 2+ channels, since the Ca 2+ in¯ux process through SOCC depends on the degree of ®lling of the internal Ca 2+ stores (Parekh & Penner, 1997) . The data in Figure 6 suggests that trans-resveratrol and Ca 2+ are not competing for the same site on the calcium channel, since the transresveratrol inhibition of thrombin induced elevation of [Ca 2+ ] i could not be overcome by increasing the extracellular Ca 2+ .
Other types of phytoestrogens (apigenin, daidzein, genistein, genistein-glucoside) showed a similar mode of action to trans-resveratrol on thrombin-stimulated platelets, by inhibiting Ca 2+ in¯ux. Genistein-glucoside, being a very hydrophilic compound, is a tool to explore indirectly if the phytoestrogens have their primary targets on the platelet surface rather than on an intracellular target. Genistein and genistein-glucoside have a very similar time course of action, inhibiting Ca 2+ in¯ux apparently at the moment of their contact with the platelet (Figure 10 ). This evidence also indirectly supports the hypothesis that phytoestrogens act upon the platelet surface, directly or indirectly changing Ca 2+ channel activity. The key point to resolve is whether trans-resveratrol and other phytoestrogens act directly on the cell surface or must penetrate the inside of the platelet. This could be clari®ed by a direct radiolabelled ligand binding and anity labelling experiment to platelet membranes. It would be of interest to explore what intracellular signal transduction pathways are involved in the trans-resveratrol action. Examining whether trans-resveratrol and other phytoestrogens change the phosphorylation state of the intracellular targets would be important since several phytoestrogens have been shown to act as tyrosine kinase inhibitors, although high concentrations are required to inhibit a variety of kinases. For genistein the IC 50 for the epidermal growth factor receptor tyrosine kinase is 2.6 mM, for p60 v-src the IC 50 =25 mM and for protein kinase C and protein kinase A the IC 50 4100 mM (Akiyama et al., 1987) .
In our experiments we observed inhibition of thrombin eects by genistein and the other phytoestrogens daidzein, apigenin and trans-resveratrol in the 0.1 ± 10 mM concentration range ( Figure 9 and data not shown). Since daidzein is used as an inactive analogue of genistein in tyrosine kinase experiments (Akiyama et al., 1987) , and since both daidzein and genistein produced the same degree of inhibition of thrombin ( Figure 9 ) this would argue against these compounds producing the inhibition of Ca 2+ in¯ux in platelets by inhibiting a tyrosine kinase.
The levels of trans-resveratrol in red wine are typically in the 10 ± 100 mM (0.4 ± 4 mg l 71 ) range (Soleas et al., 1997) , with wine from Cabernet Savignon having levels as high as 7 mg l
71
. Also the presence of trans-resveratrol-glucoside (piceid) in wine may also contribute to the levels of trans-resveratrol in the blood. Even though much experimental data supports the biological activity of trans-resveratrol in vivo, following regular wine consumption in man (e.g. Tham et al., 1998) , no serum levels have been reported. Also there is no data on clearance from the blood and ®rst-pass eects in the portal circulation of the liver (e.g. Gehm et al., 1997) . The data presented by PaceAsciak et al. (1996) , in which humans had consumed 2 mg of trans-resveratrol per day, showing decreased platelet activity was very convincing. This amount of trans-resveratrol is equivalent to consuming approximately 1 L of a typical red wine per day (Soleas et al., 1997) . We observed that genistein and genistein-glucoside (Figures 9 and 10) were able to inhibit thrombin induced elevations of [Ca 2+ ] i similar to that seen with trans-resveratrol (Figures 2 and 3 ). After consuming a soybean our-based meal on two occasions, 6 days apart, the levels of genistein and daidzein reached peak plasma levels of 4 and 3 mM respectively, with elimination half-lives of 5.7 and 4.7 h, respectively (King & Bursill, 1998) . These levels of genistein and daidzein were able to inhibit the ability of thrombin to elevate [Ca 2+ ] i in platelets in vitro (Figure 9 ). In another study involving 14 Japanese men, average age 55 years on an uncontrolled diet, the plasma phytoestrogen levels were approximately 0.4 mM (Adlercreutz et al., 1993) .
In conclusion, since phytoestrogenic compounds are present in a variety of foods (Mikscicek, 1995) , their Ca 2+ -channels blocking action may be potentially bene®cial in the prevention and management of cardiovascular disease and other cardiovascular dysfunctions in which thrombosis plays a role.
